Publication Date
| In 2025 | 4 |
| Since 2024 | 7 |
| Since 2021 (last 5 years) | 7 |
| Since 2016 (last 10 years) | 8 |
| Since 2006 (last 20 years) | 56 |
Descriptor
| Outcomes of Treatment | 77 |
| Stimulants | 77 |
| Drug Therapy | 67 |
| Attention Deficit Disorders | 35 |
| Children | 32 |
| Attention Deficit… | 29 |
| Hyperactivity | 29 |
| Symptoms (Individual… | 19 |
| Adolescents | 13 |
| Comparative Analysis | 11 |
| Intervention | 9 |
| More ▼ | |
Source
Author
| Pelham, William E., Jr. | 6 |
| Swanson, James M. | 6 |
| Vitiello, Benedetto | 6 |
| Arnold, L. Eugene | 5 |
| Hechtman, Lily | 5 |
| Hoza, Betsy | 5 |
| Wigal, Timothy | 5 |
| Lerner, Marc | 4 |
| Abikoff, Howard | 3 |
| Abikoff, Howard B. | 3 |
| Elliott, Glen | 3 |
| More ▼ | |
Publication Type
| Journal Articles | 74 |
| Reports - Research | 52 |
| Information Analyses | 12 |
| Reports - Evaluative | 9 |
| Guides - Non-Classroom | 2 |
| Opinion Papers | 2 |
| Reports - Descriptive | 2 |
| Reports - General | 1 |
| Tests/Questionnaires | 1 |
Audience
| Researchers | 3 |
| Practitioners | 1 |
| Support Staff | 1 |
| Teachers | 1 |
Location
| Brazil | 1 |
| California | 1 |
| Canada | 1 |
| Denmark | 1 |
| New York | 1 |
| Pennsylvania | 1 |
| Sweden | 1 |
Laws, Policies, & Programs
Assessments and Surveys
| Conners Rating Scales | 2 |
| Continuous Performance Test | 1 |
| Hamilton Rating Scale for… | 1 |
| State Trait Anxiety Inventory | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkBrooke S. G. Molina; Heather M. Joseph; Heidi L. Kipp; Sarah L. Pedersen; David J. Kolko; Rachel A. Lindstrom; Daniel J. Bauer; Geetha A. Subramaniam – Journal of Attention Disorders, 2025
Objective: To test whether pediatrician training leads to provider utilization of stimulant diversion prevention strategies as reported by adolescent patients with ADHD. Methods: Pediatric practices received a stimulant diversion prevention workshop (SDP) or continued treatment-as-usual (TAU) in a cluster-randomized controlled trial. Surveys were…
Descriptors: Pediatrics, Physicians, Adolescents, Stimulants
Craig B. H. Surman; Daniel M. Walsh; Joseph B. Bond – Journal of Attention Disorders, 2024
Objective: We appraised whether FDA registration trials for ADHD pharmacotherapy in adults provides comparable information to inform treatment expectations. Method: Comparison of ADHD outcome measure patterns in ADHD pharmacotherapy FDA drug label source studies. Results: Among stimulants, from fixed-dose titration data, amphetamine agents had…
Descriptors: Drug Therapy, Attention Deficit Hyperactivity Disorder, Adults, Stimulants
Yuwen Hung; Allison Green; Caroline Kelberman; Schuyler Gaillard; James Capella; Nicole Rudberg; John D. E. Gabrieli; Joseph Biederman; Mai Uchida – Journal of Attention Disorders, 2024
Objective: Stimulant medications are the main treatment for Attention Deficit Hyperactivity Disorder (ADHD), but overall treatment efficacy in adults has less than a 60% response rate. This study aimed to identify neural and cognitive markers predictive of longitudinal improvement in response to stimulant treatment in drug-naïve adults with ADHD.…
Descriptors: Stimulants, Drug Therapy, Attention Deficit Hyperactivity Disorder, Adults
Iris L. Rapoport; Annabeth P. Groenman – Journal of Attention Disorders, 2025
Objective: Stimulant medications are the primary pharmacological intervention for ADHD, yet our understanding of how sex and gender impact stimulant treatment outcomes remains limited. Clinical guidelines do not differ for female and male individuals despite possible sex and gender-related differences in effectiveness, adverse events, and…
Descriptors: Attention Deficit Hyperactivity Disorder, Gender Differences, Physiology, Stimulants
Frances R. Levin; John J. Mariani; Martina Pavlicova; C. Jean Choi; Cale Basaraba; Amy L. Mahony; Daniel J. Brooks; Christina A. Brezing; Nasir Naqvi – Journal of Attention Disorders, 2024
Objective: To determine if treatment of co-occurring adult ADHD and Cannabis Use Disorder (CUD) with extended-release mixed amphetamine salts (MAS-ER) would be effective at improving ADHD symptoms and promoting abstinence. Method: A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28)…
Descriptors: Comorbidity, Attention Deficit Hyperactivity Disorder, Marijuana, Drug Abuse
Destin Groff; Wen-Jan Tuan; Kraig Holt; James R. Latronica; Curtis Bone – Journal of Attention Disorders, 2025
Introduction: Prescription stimulants are an effective FDA approved treatment for attention deficit hyperactivity disorder (ADHD) however their safety has come under scrutiny. Multiple studies demonstrate safe use in pediatric populations, but prescriptions are increasing to adults and it is not evident which comorbidities might place people at…
Descriptors: Heart Disorders, Stimulants, Attention Deficit Hyperactivity Disorder, Drug Therapy
Benjamin Johnson; Tianze Sun; Leo Wu; Stella Seal; Daniel Stjepanovic; Gary Chan; Janni Leung – Journal of Attention Disorders, 2025
Background: TikTok has become a significant influence on public health perceptions, especially regarding ADHD. With its expansive reach among younger demographics, TikTok content has the potential to shape public understanding and behaviors related to ADHD treatment. This study analyzed how prescription stimulants are depicted on TikTok to assess…
Descriptors: Social Media, Computer Mediated Communication, Attention Deficit Hyperactivity Disorder, Stimulants
Fostick, Leah – Journal of Speech, Language, and Hearing Research, 2017
Purpose: "The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition" notes that attention-deficit/hyperactivity disorder (ADHD) diagnosed in childhood will persist into adulthood among at least some individuals. There is a paucity of evidence, however, regarding whether other difficulties that often accompany childhood…
Descriptors: Attention Deficit Hyperactivity Disorder, Stimulants, Drug Therapy, Adults
Molina, Brooke S. G.; Hinshaw, Stephen P.; Arnold, L. Eugene; Swanson, James M.; Pelham, William E.; Hechtman, Lily; Hoza, Betsy; Epstein, Jeffery N.; Wigal, Timothy; Abikoff, Howard B.; Greenhill, Laurence L.; Jensen, Peter S.; Wells, Karen C.; Vitiello, Benedetto; Gibbons, Robert D.; Howard, Andrea; Houck, Patricia R.; Hur, Kwan; Lu, Bo; Marcus, Sue – Journal of the American Academy of Child & Adolescent Psychiatry, 2013
Objective: To determine long-term effects on substance use and substance use disorder (SUD), up to 8 years after childhood enrollment, of the randomly assigned 14-month treatments in the multisite Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA; n = 436); to test whether medication at follow-up, cumulative…
Descriptors: Prevention, Substance Abuse, Attention Deficit Hyperactivity Disorder, Adolescents
Mattos, Paulo; Rodrigues Louza, Mario; Fernandes Palmini, Andre Luis; de Oliveira, Irismar Reis; Lopes Rocha, Fabio – Journal of Attention Disorders, 2013
The available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD. Objective: To assess the effectiveness of Methyphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. Method: A 12-week, multicenter, open-label trial involving 60 patients was used. The…
Descriptors: Quality of Life, Drug Therapy, Attention Deficit Hyperactivity Disorder, Outcomes of Treatment
Niederhofer, Helmut – Journal of Attention Disorders, 2012
Objective: Antidepressants, in particular Atomextine, along with stimulants have demonstrated benefit in the treatment of ADHD. Agomelatine is a new antidepressant with additional affinities to the melatonergic system. As ADHD has been associated with sleep disorders, it is assumed that Agomelatiine might serve as a therapeutic alternative to…
Descriptors: Adolescents, Sleep, Attention Deficit Hyperactivity Disorder, Patients
Reichow, Brian; Volkmar, Fred R.; Bloch, Michael H. – Journal of Autism and Developmental Disorders, 2013
Many children with pervasive developmental disorders (PDD) exhibit behaviors and symptoms of attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of medications for treating ADHD symptoms in children with PDD by identifying all double-blind, randomized, placebo-controlled trials examining the efficacy of…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Outcomes of Treatment
Martens, Marilee A.; Seyfer, Daisha L.; Andridge, Rebecca R.; Foster, Jessica E. A.; McClure, Kelsey E.; Coury, Daniel L. – Research in Developmental Disabilities: A Multidisciplinary Journal, 2013
Williams syndrome (WS) is a genetic condition characterized by a unique neurocognitive and behavioral profile, including increased incidence of attention deficit/hyperactivity disorder (ADHD). The purpose of the present study was to examine the perceived helpfulness and side effects of medications used to treat ADHD (methylphenidate class,…
Descriptors: Attention Deficit Hyperactivity Disorder, Genetic Disorders, Caregiver Attitudes, Stimulants
Tsiouris, John A.; Kim, Soh-Yule; Brown, W. Ted; Pettinger, Jill; Cohen, Ira L. – Journal of Autism and Developmental Disorders, 2013
The use of psychotropics by categories and the reason for their prescription was investigated in a large scale study of 4,069 adults with ID, including those with autism spectrum disorder, in New York State. Similar to other studies it was found that 58 % (2,361/4,069) received one or more psychotropics. Six percent received typical, 6 % received…
Descriptors: Aggression, Anxiety Disorders, Autism, Psychiatry
Wilens, Timothy E.; Bukstein, Oscar; Brams, Matthew; Cutler, Andrew J.; Childress, Ann; Rugino, Thomas; Lyne, Andrew; Grannis, Kara; Youcha, Sharon – Journal of the American Academy of Child & Adolescent Psychiatry, 2012
Objective: To examine efficacy, tolerability, and safety of guanfacine extended release (GXR; less than or equal to 4 mg/d) adjunctive to a long-acting psychostimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years of age with suboptimal, but partial, response to psychostimulant…
Descriptors: Attention Deficit Hyperactivity Disorder, Safety, Rating Scales, Severity (of Disability)
